Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
100%
Confidence Interval
55%
Graft-versus-host Disease (GvHD)
49%
Graft-versus-host Disease Prophylaxis
41%
Allogeneic Blood or Marrow Transplantation
40%
Multiple Myeloma
27%
Nonmyeloablative
27%
Haploidentical Transplantation
25%
Allogeneic Bone Marrow Transplantation
25%
Overall Survival
25%
Relapse-free Survival
24%
Allogeneic Transplantation
23%
Non-relapse Mortality
22%
Transplantation
20%
Peripheral Blood
19%
Marrow Transplantation
19%
Allogeneic Blood
19%
High Dose
19%
Hazard Ratio
18%
Myeloablative Conditioning
16%
Cumulative Incidence
15%
Acute Lymphoblastic Leukemia
14%
Severe Aplastic Anemia
14%
CD38
14%
HLA-haploidentical
12%
Allograft
12%
Mismatched Related Donor
12%
Haploidentical
12%
Donor Age
11%
Bone Marrow Transplantation
11%
Haploidentical Donor
11%
Myeloma Therapy
10%
Immunosuppressive Therapy
10%
Acute Myeloid Leukemia
10%
Hematological Malignancies
10%
Graft Source
9%
Immunosuppression
9%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
9%
Total Body Irradiation
9%
HLA Matching
8%
Initial Treatment
8%
Older Adults
8%
Blood or Marrow Transplantation
8%
Conventional Chemotherapy
8%
Tyrosine Kinase Inhibitor
7%
Haploidentical Peripheral Blood Stem Cell Transplantation
7%
Alternative Donor
7%
Reduced-intensity Conditioning
7%
Chronic Lymphocytic Leukemia
7%
Minimal Residual Disease
7%
Medicine and Dentistry
Cyclophosphamide
92%
Graft Versus Host Reaction
66%
Prophylaxis
48%
Multiple Myeloma
34%
Transplantation
27%
Overall Survival
26%
Drug Megadose
25%
Disease
22%
Nonmyeloablative Conditioning
21%
Hazard Ratio
20%
Cumulative Incidence
19%
Recurrence Free Survival
17%
Allotransplantation
16%
Haploidentical Transplantation
15%
Immunosuppressive Treatment
13%
Chronic Graft Versus Host Disease
11%
Acute Graft Versus Host Disease
10%
Whole Body Radiation
10%
Progression Free Survival
10%
Allogenic Bone Marrow Transplantation
10%
Bone Marrow Transplantation
9%
Clinical Trial
9%
Acute Myeloid Leukemia
8%
Peripheral Blood Stem Cell Transplantation
7%
Positron Emission Tomography
7%
Biological Marker
7%
Nephron
7%
RNA Immunization
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Natural Killer Cell
7%
Myelofibrosis
7%
Focal Segmental Glomerulosclerosis
7%
Granulocyte Macrophage Colony Stimulating Factor
7%
Antibody Response
7%
Morphology
7%
Immunoglobulin A Nephropathy
7%
Lenalidomide
7%
Peripheral T-Cell Lymphoma
7%
Acute B-Cell Lymphoblastic Leukemia
7%
Microangiopathy
7%
Chimeric Antigen Receptor T-Cell
7%
Aplastic Anemia
7%
Acute Lymphoblastic Leukemia
7%
HIV-associated Nephropathy
7%
Diagnosis
7%
Immune Checkpoint Inhibitor
7%
Daratumumab
7%
Acute Promyelocytic Leukemia
7%
Emergency Department
7%
Prospective Cohort Study
7%
Immunology and Microbiology
Cyclophosphamide
100%
Graft-Versus-Host Disease
65%
Transplant Procedure
32%
Conditioning
31%
Overall Survival
30%
Recurrence Free Survival
27%
Drug Megadose
26%
Allotransplantation
21%
Multiple Myeloma
20%
Bone Marrow Transplantation
18%
Chronic Graft Versus Host Disease
15%
Peripheral Blood Stem Cell Transplantation
14%
Acute Graft Versus Host Disease
14%
Aplastic Anemia
14%
Allotransplantation
12%
Vaccine Efficacy
11%
Immunosuppression
10%
Allogeneic Bone Marrow Transplantation
10%
Immunosuppressive Therapy
10%
Cytokine Release Syndrome
10%
Haplotype
8%
Myeloid
8%
Vaccination Policy
8%
Progression Free Survival
8%
B Cell
7%
CD34
7%
Host
7%
Severe Acute Respiratory Syndrome Coronavirus 2
7%
Human Immunodeficiency Virus 1
7%
Natural Killer Cell
7%
B Cell Maturation Antigen
7%
Chimeric Antigen Receptor T-Cell
7%
Central Nervous System
7%
Antibody Response
7%
Daratumumab
7%
Granulocyte Macrophage Colony-Stimulating Factor
7%
CD38
7%
Histocompatibility
7%
Lenalidomide
7%
Immunoglobulin Heavy Chain
7%
IgA Nephropathy
7%
Event Free Survival
5%